Request Demo
Last update 28 Feb 2026
BL-M24D1
Last update 28 Feb 2026
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms BL M24D1 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Related
5
Clinical Trials associated with BL-M24D1NCT07279428
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M24D1 for Injection in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
NCT07232524
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M24D1 for Injection in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT07255898
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characteristics and Preliminary Efficacy of BL-M24D1 for Injection in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
100 Clinical Results associated with BL-M24D1
Login to view more data
100 Translational Medicine associated with BL-M24D1
Login to view more data
100 Patents (Medical) associated with BL-M24D1
Login to view more data
100 Deals associated with BL-M24D1
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Gastrointestinal Neoplasms | Phase 1 | China | 12 Jan 2026 | |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | China | 10 Dec 2025 | |
| Squamous cell carcinoma of head and neck metastatic | Phase 1 | China | 10 Dec 2025 | |
| Refractory Multiple Myeloma | Phase 1 | China | 01 Dec 2025 | |
| Hematologic Neoplasms | Phase 1 | China | 20 Nov 2025 | |
| Locally Advanced Lung Non-Small Cell Carcinoma | Phase 1 | China | 11 Nov 2025 | |
| Locally Advanced Malignant Solid Neoplasm | IND Approval | China | 21 Oct 2025 | |
| Metastatic Solid Tumor | IND Approval | China | 21 Oct 2025 | |
| Recurrent Hematologic Malignancy | IND Approval | China | 21 Oct 2025 | |
| Refractory Hematologic Malignancy | IND Approval | China | 21 Oct 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free